Last reviewed · How we verify
Visicol
Visicol is a Small molecule drug developed by Braintree Laboratories. It is currently in Phase 3 development.
Visicol is a tablet preparation used for colonoscopy, specifically studied in preparation for the procedure. It is compared to HalfLytely in clinical trials, such as the study "Patient Preference With Visicol Tablet Preparation for Colonoscopy" conducted by the Mayo Clinic.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Visicol |
|---|---|
| Sponsor | Braintree Laboratories |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy. (PHASE3)
- Patient Preference With Visicol Tablet Preparation for Colonoscopy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Visicol CI brief — competitive landscape report
- Visicol updates RSS · CI watch RSS
- Braintree Laboratories portfolio CI
Frequently asked questions about Visicol
What is Visicol?
Who makes Visicol?
What development phase is Visicol in?
Related
- Manufacturer: Braintree Laboratories — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing